AstraZeneca's Datroway Approved as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
The U.S. FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) as a first-line treatment for metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 inhibitor therapy.
Tickers: $AZN
Topics: antibody-drug conjugate cancer treatment pharmaceuticals